Questões de Concurso Público Prefeitura de Itapiranga - SC 2026 para Professor de Língua Estrangeira (Inglês)
Foram encontradas 9 questões
Ano: 2026
Banca:
AMEOSC
Órgão:
Prefeitura de Itapiranga - SC
Prova:
AMEOSC - 2026 - Prefeitura de Itapiranga - SC - Professor de Língua Estrangeira (Inglês) |
Q4313260
Inglês
Texto associado
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
After reading the article, students compare the headline,
financial projections, quoted analysts and descriptions of
clinical development. They then produce a short
English-language briefing distinguishing facts, forecasts
and corporate interests.
Consider the assertions:
I. The activity is compatible with a language-education approach that treats English as a means of accessing and critically examining international information.
BECAUSE
II. Students must analyse how linguistic choices and source positions influence the representation of a contemporary event.
Mark the CORRECT alternative.
Consider the assertions:
I. The activity is compatible with a language-education approach that treats English as a means of accessing and critically examining international information.
BECAUSE
II. Students must analyse how linguistic choices and source positions influence the representation of a contemporary event.
Mark the CORRECT alternative.
Ano: 2026
Banca:
AMEOSC
Órgão:
Prefeitura de Itapiranga - SC
Prova:
AMEOSC - 2026 - Prefeitura de Itapiranga - SC - Professor de Língua Estrangeira (Inglês) |
Q4313261
Inglês
Texto associado
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
A teacher prepares an audio adaptation of the article and
asks students to identify the difference between
confirmed information and market projections. Before
listening, the teacher provides the categories confirmed
transaction, clinical expectation, and financial estimate.
Which procedure most effectively develops the intended
listening skill?
Ano: 2026
Banca:
AMEOSC
Órgão:
Prefeitura de Itapiranga - SC
Prova:
AMEOSC - 2026 - Prefeitura de Itapiranga - SC - Professor de Língua Estrangeira (Inglês) |
Q4313262
Inglês
Texto associado
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
Read the excerpt:
"Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials."
Consider the statements:
I. The modal verb could expresses a projected commercial possibility rather than a guaranteed result.
II. The clause introduced by if establishes a condition for the estimated sales performance.
III. The simple present form succeeds refers to a habitual event repeatedly observed in previous trials.
Mark the alternative that presents only the CORRECT statements.
"Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials."
Consider the statements:
I. The modal verb could expresses a projected commercial possibility rather than a guaranteed result.
II. The clause introduced by if establishes a condition for the estimated sales performance.
III. The simple present form succeeds refers to a habitual event repeatedly observed in previous trials.
Mark the alternative that presents only the CORRECT statements.
Ano: 2026
Banca:
AMEOSC
Órgão:
Prefeitura de Itapiranga - SC
Prova:
AMEOSC - 2026 - Prefeitura de Itapiranga - SC - Professor de Língua Estrangeira (Inglês) |
Q4313263
Inglês
Texto associado
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
A teacher uses the article to discuss how pharmaceutical
research, regulation, investment and public
communication interact across national borders. The
teacher wants to avoid turning the lesson into either
commercial promotion or an unsupported debate about
medical treatment. Register T for true statements and F
for false statements.
(__) Students may compare how the article distinguishes clinical evidence, regulatory decisions and market expectations.
(__) The lesson may examine how international news circulates through English and influences access to scientific and economic information.
(__) Students should evaluate the therapeutic effectiveness of BPL-003 according to their personal experiences with mental-health treatments.
(__) The teacher may require students to distinguish information reported in the article from conclusions not supported by the text.
Mark the alternative that presents the CORRECT sequence.
(__) Students may compare how the article distinguishes clinical evidence, regulatory decisions and market expectations.
(__) The lesson may examine how international news circulates through English and influences access to scientific and economic information.
(__) Students should evaluate the therapeutic effectiveness of BPL-003 according to their personal experiences with mental-health treatments.
(__) The teacher may require students to distinguish information reported in the article from conclusions not supported by the text.
Mark the alternative that presents the CORRECT sequence.
Ano: 2026
Banca:
AMEOSC
Órgão:
Prefeitura de Itapiranga - SC
Prova:
AMEOSC - 2026 - Prefeitura de Itapiranga - SC - Professor de Língua Estrangeira (Inglês) |
Q4313264
Inglês
Texto associado
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
The article presents Lilly's acquisition of AtaiBeckley as
part of a broader corporate strategy. Based on the
information provided, the acquisition may be interpreted
as an attempt to:
Ano: 2026
Banca:
AMEOSC
Órgão:
Prefeitura de Itapiranga - SC
Prova:
AMEOSC - 2026 - Prefeitura de Itapiranga - SC - Professor de Língua Estrangeira (Inglês) |
Q4313269
Inglês
Read the sentences and evaluate the meanings and
grammatical uses of the highlighted phrasal verbs.
(__) In "The research team carried out several interviews," carried out means conducted.
(__) In "The school turned down the proposal," the object pronoun may be correctly placed as in "The school turned it down."
(__) In "The volunteer looked after the children," the phrasal verb is separable and may be rewritten as "The volunteer looked the children after."
(__) In "She eventually got over the disappointment," got over means examined the disappointment carefully.
Mark T for true statements and F for false statements. Then select the alternative that presents the CORRECT sequence
(__) In "The research team carried out several interviews," carried out means conducted.
(__) In "The school turned down the proposal," the object pronoun may be correctly placed as in "The school turned it down."
(__) In "The volunteer looked after the children," the phrasal verb is separable and may be rewritten as "The volunteer looked the children after."
(__) In "She eventually got over the disappointment," got over means examined the disappointment carefully.
Mark T for true statements and F for false statements. Then select the alternative that presents the CORRECT sequence
Ano: 2026
Banca:
AMEOSC
Órgão:
Prefeitura de Itapiranga - SC
Prova:
AMEOSC - 2026 - Prefeitura de Itapiranga - SC - Professor de Língua Estrangeira (Inglês) |
Q4313270
Inglês
A teacher intends to address generative artificial
intelligence through English-language materials.
Students will compare an institutional guideline, a news
report and a promotional text produced by a technology
company. Mark T for true statements and F for false
ones.
(__)Comparing the three genres may reveal how purpose and authorship influence the presentation of the same technology.
(__)Examining evidence and lexical choices can help students distinguish information from promotional framing.
(__)The lesson should determine whether the technology is socially beneficial through a vote based on students' initial impressions.
(__)Producing citation rules for classroom use can connect language learning with responsible participation in digital environments.
Mark the alternative that presents the CORRECT sequence.
(__)Comparing the three genres may reveal how purpose and authorship influence the presentation of the same technology.
(__)Examining evidence and lexical choices can help students distinguish information from promotional framing.
(__)The lesson should determine whether the technology is socially beneficial through a vote based on students' initial impressions.
(__)Producing citation rules for classroom use can connect language learning with responsible participation in digital environments.
Mark the alternative that presents the CORRECT sequence.
Ano: 2026
Banca:
AMEOSC
Órgão:
Prefeitura de Itapiranga - SC
Prova:
AMEOSC - 2026 - Prefeitura de Itapiranga - SC - Professor de Língua Estrangeira (Inglês) |
Q4313271
Inglês
Read the sentence:
"By the time the meeting started, the committee had already reviewed the revised proposal."
Which interpretation accurately explains the relationship between the verb forms?
"By the time the meeting started, the committee had already reviewed the revised proposal."
Which interpretation accurately explains the relationship between the verb forms?
Ano: 2026
Banca:
AMEOSC
Órgão:
Prefeitura de Itapiranga - SC
Prova:
AMEOSC - 2026 - Prefeitura de Itapiranga - SC - Professor de Língua Estrangeira (Inglês) |
Q4313273
Inglês
A school's Projeto Político Pedagógico (PPP) identifies
low student participation in community decisions and
proposes strengthening communication between the
school, families and local organizations. The English
department plans a multilingual digital bulletin containing
interviews, public information and student reports.
Consider the assertions.
I.The project can connect the English curriculum with the objectives established collectively in the PPP.
BECAUSE
II.Students use language to investigate community issues, address real audiences and participate in the school's communication practices.
Mark the alternative that correctly assesses the relationship between the two assertions.
I.The project can connect the English curriculum with the objectives established collectively in the PPP.
BECAUSE
II.Students use language to investigate community issues, address real audiences and participate in the school's communication practices.
Mark the alternative that correctly assesses the relationship between the two assertions.
Conheça nossos planos